Want to see AU:IDX full AI Analyst Report?
IDX Stock Chart & Stats
AU$2.05
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$2.05
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$1.91 - AU$3.07
Previous CloseN/A
Volume370.59K
Average Volume (3M)911.20K
Market Cap
AU$782.99M
Enterprise ValueAU$1.53K
Total Cash (Recent Filing)AU$34.12M
Total Debt (Recent Filing)AU$841.54M
Price to Earnings (P/E)55.9
Beta0.62
Next Earnings
Aug 25, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend Yield3.43%
Share Statistics
EPS (TTM)0.04
Shares Outstanding373,066,530
10 Day Avg. Volume1,057,226
30 Day Avg. Volume911,197
Financial Highlights & Ratios
PEG Ratio-1.58
Price to Book (P/B)1.12
Price to Sales (P/S)1.24
P/FCF Ratio55.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.20Price Target Upside56.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.14
Revenue Forecast (FY)AU$850.15M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained double-digit revenue growth expands clinic scale and referral reach, enabling better fixed-cost absorption and investment in capacity. Over 2-6 months this supports organic market share gains and underpins longer-term growth initiatives like new clinics or service expansion.
High Gross MarginA very high gross margin indicates the core imaging services are structurally lucrative, allowing the company to fund overhead, invest in technology, and subsidize lower-margin services. This margin strength supports durable profitability if utilization and payer mixes remain stable.
Improved LeverageModerate and improving leverage enhances financial flexibility for capital expenditure and acquisitions while keeping interest burden manageable. Over the medium term this supports strategic expansion without overstressing the balance sheet or forcing dilutive capital raises.
Bears Say
Low Net Profit MarginA very low net margin means minimal buffer versus cost shocks and limited internal earnings to fund growth or returns. Even with high revenues, persistent low net profitability undermines sustainable free cash generation and shareholder value over the medium term.
Declining Free Cash FlowA near-60% drop in free cash flow signals weaker conversion of earnings into spendable cash, constraining reinvestment, debt servicing, and dividends. If this trend continues it could force external financing or slow expansion, stressing medium-term operational plans.
Low Return On EquityROE under 1% indicates the company struggles to generate returns on invested capital, limiting capacity to self-fund growth and diminishing long-term shareholder value. Structural improvements in margin or capital efficiency are required to remediate this weakness.
Integral Diagnostics Ltd. News
IDX FAQ
What was Integral Diagnostics Ltd.’s price range in the past 12 months?
Integral Diagnostics Ltd. lowest share price was AU$1.91 and its highest was AU$3.07 in the past 12 months.
What is Integral Diagnostics Ltd.’s market cap?
Integral Diagnostics Ltd.’s market cap is AU$782.99M.
When is Integral Diagnostics Ltd.’s upcoming earnings report date?
Integral Diagnostics Ltd.’s upcoming earnings report date is Aug 25, 2026 which is in 19 days.
How were Integral Diagnostics Ltd.’s earnings last quarter?
Integral Diagnostics Ltd. released its earnings results on Feb 23, 2026. The company reported AU$0.024 earnings per share for the quarter, missing the consensus estimate of AU$0.056 by -AU$0.032.
Is Integral Diagnostics Ltd. overvalued?
According to Wall Street analysts Integral Diagnostics Ltd.’s price is currently Undervalued.
Does Integral Diagnostics Ltd. pay dividends?
Integral Diagnostics Ltd. pays a Semiannually dividend of AU$0.033 which represents an annual dividend yield of 3.43%. See more information on Integral Diagnostics Ltd. dividends here
What is Integral Diagnostics Ltd.’s EPS estimate?
Integral Diagnostics Ltd.’s EPS estimate is 0.06.
How many shares outstanding does Integral Diagnostics Ltd. have?
Integral Diagnostics Ltd. has 373,066,530 shares outstanding.
What happened to Integral Diagnostics Ltd.’s price movement after its last earnings report?
Integral Diagnostics Ltd. reported an EPS of AU$0.024 in its last earnings report, missing expectations of AU$0.056. Following the earnings report the stock price went down -5.83%.
Which hedge fund is a major shareholder of Integral Diagnostics Ltd.?
Currently, no hedge funds are holding shares in AU:IDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Integral Diagnostics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$3.20 (56.10% Upside)
AU$3.20 (56.10% Upside)
Blogger Sentiment
Bullish
AU:IDX Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$125.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.34%
12-Months-Change
Fundamentals
Return on Equity
3.43%
Trailing 12-Months
Asset Growth
4.81%
Trailing 12-Months
Company Description
Integral Diagnostics Ltd.
Integral Diagnostics Limited operates within the healthcare sector, providing essential diagnostic imaging services. These services are delivered to general practitioners, medical specialists, allied health professionals, and their patients across Australia and New Zealand. The company manages its service delivery through a network of 67 radiology clinics. Integral Diagnostics was incorporated in 2008 and maintains its primary corporate office in Melbourne, Australia.
IDX Stock 12 Month Forecast
Average Price Target
AU$3.20
▲(56.10% Upside)
Technical Analysis
Healius Limited
―
BCAL Diagnostics Limited
―
Sonic Healthcare Limited
―
Australian Clinical Labs Ltd
―
Imagion Biosystems Ltd.
―







